DrugPatentWatch Database Preview
Leo Labs Company Profile
What is the competitive landscape for LEO LABS, and what generic alternatives to LEO LABS drugs are available?
There are sixteen US patents protecting LEO LABS drugs.
There are forty-eight patent family members on LEO LABS drugs in twenty-four countries and fourteen supplementary protection certificates in ten countries.
Summary for Leo Labs
| International Patents: | 48 |
| US Patents: | 16 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Leo Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | RX | Yes | Yes | 6,844,013 | ➤ Sign Up | ➤ Sign Up | ||||
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | RX | Yes | Yes | 7,410,656 | ➤ Sign Up | ➤ Sign Up | ||||
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-002 | Jan 23, 2012 | RX | Yes | Yes | 8,536,163 | ➤ Sign Up | ➤ Sign Up | ||||
| Leo Labs | PICATO | ingenol mebutate | GEL;TOPICAL | 202833-001 | Jan 23, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for LEO LABS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 0.05% | ➤ Subscribe | 2016-01-27 |
Non-Orange Book US Patents for Leo Labs
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,603,822 | Therapeutic compositions | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Leo Labs Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2013049715 | ➤ Sign Up |
| Canada | 2301082 | ➤ Sign Up |
| Japan | 2009519314 | ➤ Sign Up |
| Norway | 20083150 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Leo Labs Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2013 00024 | Denmark | ➤ Sign Up | |
| 185 | Luxembourg | ➤ Sign Up | PRODUCT NAME: INGENANE OU UN DERIVE(SEL OU ESTER)DE CELUI-CI |
| 2014000075 | Germany | ➤ Sign Up | PRODUCT NAME: INGENOLMEBUTAT ODER EIN DERIVAT (SALZ ODER ESTER) DAVON; REGISTRATION NO/DATE: EU/1/12/796 20121115 |
| 1015413/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
